XML 22 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Revenue $ 4,346 $ 2,428
Operating expenses:    
Cost of revenue 7,099 5,979
Sales and marketing 16,463 16,404
General and administrative 20,156 19,254
Amortization of acquired intangible assets 688 2,021
Research and development 5,992 7,252
Total operating expenses 50,398 50,910
Operating loss (46,052) (48,482)
Other income (expense):    
Interest income 322 424
Interest expense (26) (416)
Change in fair value - Senior Secured Convertible Note 5,394 (2,980)
Loss on issue and offering costs - Senior Secured Convertible Note (1,186)
Debt extinguishments loss - Senior Secured Convertible Note (5,167) (26)
Other income (expense), net 523 (4,184)
Loss before provision for income tax (45,529) (52,666)
Provision for income taxes
Net loss attributable to Lucid Diagnostics Inc. (45,529) (52,666)
Less: Deemed dividend on Series A and Series A-1 Convertible Preferred Stock (7,496)
Net loss attributable to Lucid Diagnostics Inc. common stockholders $ (53,025) $ (52,666)
Net loss per share - basic [1] $ (1.05) $ (1.26)
Net loss per share - diluted [1] $ (1.05) $ (1.26)
Weighted average common shares outstanding, basic 50,515,773 41,756,129
Weighted average common shares outstanding, diluted 50,515,773 41,756,129
[1] - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.